We provide continuous financial coverage including stock performance, earnings expectations, and broader economic indicators.
As of April 9, 2026, Pasithea Therapeutics Corp. (KTTA) trades at a current price of $0.76, marking a 0.52% decline in the most recent trading session. This analysis evaluates key technical levels, prevailing market context, and potential price action scenarios for the clinical-stage biotech stock, with no recent earnings data available for the company as of the current date. Key points for market observers to monitor include clearly defined near-term support and resistance bands, recent volume
Is Pasithea Therapeutics (KTTA) Stock Good for Passive Investors | Price at $0.76, Down 0.52% - Earnings Breakout Stocks
KTTA - Stock Analysis
3502 Comments
1591 Likes
1
Azelene
Daily Reader
2 hours ago
I’m looking for people who noticed the same thing.
👍 57
Reply
2
Maidelyn
Regular Reader
5 hours ago
Free US stock insider buying and selling tracking with regulatory filing analysis for inside information on company health. We monitor corporate insider transactions because company officers often have the best understanding of their business prospects.
👍 281
Reply
3
Duban
Registered User
1 day ago
Free US stock screening tools combined with expert analysis to help you identify undervalued companies with strong growth potential. We use sophisticated algorithms and human expertise to surface opportunities that might otherwise go unnoticed.
👍 141
Reply
4
Donnye
Legendary User
1 day ago
I don’t understand, but I feel involved.
👍 124
Reply
5
Mayari
Community Member
2 days ago
I feel like I missed something obvious.
👍 184
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.